Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether 18F-Al labeled RGD is safety and effective for cancer diagnosis and therapy response.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wuxi No. 4 People's Hospital

Criteria

Inclusion Criteria:

1. Volunteers or patients with age more than 18 yeas;

2. The patients have been diagnosed with cancer or suspected with cancer;

3. It must fulfill the ethical requirements and subjects have signed an informed consent.

Exclusion Criteria:

1. Pregnancy or nursing mothers;

2. Having drugs or alcohol dependence;

3. Hypersensitive to the active or inactive ingredients of the study drug;

4. Having attended other drug clinical trials within three months;

5. Cardiac functional insufficiency;

6. Hepatic and renal function insufficiency;

7. Hypertensive patients with serious complications;

8. Endangering the safety of life.